[Treatment for chronic kidney failure with cerebrovascular disease].
Matsumura
Osamu
O
Division of Artificial Kidney, Saitama Medical Center, Saitama Medical School.
Itakura
Yukihiro
Y
D000925:Anticoagulants / Q000008:administration & dosage; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000209:etiology* / Q000517:prevention & control; D004852:Epoxy Compounds / Q000627:therapeutic use; D006440:Hemofiltration; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000628:therapy; D006973:Hypertension / Q000150:complications / Q000628:therapy; D010531:Peritoneal Dialysis, Continuous Ambulatory; D010758:Phosphorus / Q000097:blood; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011073:Polyamines; D011095:Polyethylenes / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects; D051437:Renal Insufficiency / Q000150:complications; D012307:Risk Factors; D000069603:Sevelamer
D000925:Anticoagulants; D004852:Epoxy Compounds; D010975:Platelet Aggregation Inhibitors; D011073:Polyamines; D011095:Polyethylenes; D010758:Phosphorus; D000069603:Sevelamer